News

Date
Title
Sort By:
12/22/25
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
11/19/25
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
11/17/25
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
11/05/25
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/15/25
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
09/30/25
SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
09/04/25
SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
08/25/25
SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
08/13/25
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
05/28/25
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study